Cholangiocarcinoma (bile duct cancer) · line 2 · Ivosidenib monotherapy (ClarIDHy) — 2L+ IDH1-mutated cholangiocarcinoma
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-IVOSIDENIB-CHOLANGIO |
| ID | IND-CHOLANGIO-2L-IDH1-IVOSIDENIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-07 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-CHOLANGIOCARCINOMA |
| Sources | SRC-CLARIDHY-ABOU-ALFA-2020 SRC-ESMO-BTC-2023 SRC-NCCN-HEPATOBILIARY |
Notes
STUB — pending Clinical Co-Lead sign-off (CHARTER §6.1: ≥2 reviewers for clinical content). Aggressive-track 2L+ for IDH1-R132 mutated intrahepatic cholangiocarcinoma. NCCN cat 1 (2025 hepatobiliary); FDA Aug 2021; EMA 2023. References existing BMA-IDH1-R132-CHOLANGIO (BIO-IDH-MUTATION) for biomarker evidence linkage. Primary citation SRC-CLARIDHY-ABOU-ALFA-2020 ingested in W0-CHOLANGIO PR #456. UA access: named-patient / Servier EAP pathway only.
Used By
Algorithms
ALGO-CHOLANGIO-2L- ALGO-CHOLANGIO-2L